If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Concurrently, a preprint from the industry-backed Vital Transformation found a 50% drop in company investments into ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

J.P. Morgan releases its quarterly look-ahead days before the entire biopharma industry descends on San Francisco for the ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

Being laid off is bad enough. When companies mishandle the layoff process, it can make the situation even worse. Four ...

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...